Overview A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia Status: Completed Trial end date: 2019-10-17 Target enrollment: Participant gender: Summary The primary objective of this study is to evaluate the long-term safety and tolerability of ALKS 3831 in subjects with schizophrenia. Phase: Phase 3 Details Lead Sponsor: Alkermes, Inc.